BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ)
$2.77 0.03 (1.0949%)
Analysed BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) News Sources
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
13-05-2026
yahoo.com
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
14-05-2026
yahoo.com
BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies
14-05-2026
yahoo.com
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
15-05-2026
yahoo.com
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
22-05-2026
yahoo.com
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
26-05-2026
yahoo.com
BriaCell Therapeutics Announces Pricing of Offering
31-05-2026
yahoo.com
BriaCell Presents Positive Clinical Data at ASCO 2026
01-06-2026
yahoo.com
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
01-06-2026
yahoo.com
BriaCell Therapeutics Announces Closing of Offering
02-06-2026
yahoo.com
What is the current price of BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ)?
The current price of BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) is $2.77.
BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) since the previous trading day is $0.03.
BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) since the previous trading day is 1.0949%.
What is the most recent average sentiment score for BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ)?
The most recent average sentiment score for BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ)?
The most recent sentiment for BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ) is .
SEC-8K** Filing Available For BRIACELL THERAPEUTICS CORP (BCTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.